Masupirdine (development code: SUVN-502) is a selective serotonin 6 (5-HT6) receptor antagonist developed by Suven Life Sciences Ltd. (Hyderabad, India) for the treatment of Alzheimer's disease. This compound was investigated as an adjunct therapy to background acetylcholinesterase inhibitor (donepezil) and memantine treatment for patients with moderate AD[@semba2022][@clinicaltrialsgov].
While the primary Phase 2 trial (NCT02580305) did not meet its primary cognitive endpoint, post-hoc analyses explored effects on neuropsychiatric symptoms including agitation, aggression, and psychosis — which are common and debilitating complications of Alzheimer's disease[@menon2022].
Masupirdine is a highly selective 5-HT6 receptor antagonist. The 5-HT6 receptor is a G-protein coupled receptor (GPCR) expressed predominantly in the central nervous system, particularly in brain regions associated with cognition and emotion:
...
Masupirdine AD Agitation Trial
Overview
Masupirdine (development code: SUVN-502) is a selective serotonin 6 (5-HT6) receptor antagonist developed by Suven Life Sciences Ltd. (Hyderabad, India) for the treatment of Alzheimer's disease. This compound was investigated as an adjunct therapy to background acetylcholinesterase inhibitor (donepezil) and memantine treatment for patients with moderate AD[@semba2022][@clinicaltrialsgov].
While the primary Phase 2 trial (NCT02580305) did not meet its primary cognitive endpoint, post-hoc analyses explored effects on neuropsychiatric symptoms including agitation, aggression, and psychosis — which are common and debilitating complications of Alzheimer's disease[@menon2022].
Masupirdine is a highly selective 5-HT6 receptor antagonist. The 5-HT6 receptor is a G-protein coupled receptor (GPCR) expressed predominantly in the central nervous system, particularly in brain regions associated with cognition and emotion:
Hippocampus: High 5-HT6 expression in CA1-CA3 regions and dentate gyrus
Cortex: Both frontal and entorhinal cortices
Striatum: Moderate expression in basal ganglia
Olfactory bulb: Notable expression
Key Molecular Mechanisms
Mermaid diagram (expand to render)
Why 5-HT6 in Alzheimer's Disease?
The 5-HT6 receptor offers several theoretical advantages for AD treatment:
Cognitive enhancement: 5-HT6 antagonism increases acetylcholine and glutamate release in cortical and hippocampal regions, potentially improving memory and learning[@geldenhuys2023]
Neuroprotective effects: 5-HT6 signaling influences amyloid precursor protein (APP) processing and may affect amyloid-beta production
Neuropsychiatric symptoms: The receptor is implicated in mood and behavioral regulation, making it a target for agitation and psychosis in AD
Adjunct potential: 5-HT6 antagonists may enhance the effects of acetylcholinesterase inhibitors like donepezil
Rationale for Agitation in AD
Agitation in Alzheimer's Disease
Agitation affects up to 70% of AD patients during the disease course and represents:
A major cause of caregiver stress and institutionalization
Cognitive: Change from baseline in ADAS-Cog 11 (11-item Alzheimer's Disease Assessment Scale, Cognitive Subscale) at week 26
Secondary Endpoints
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
Mini-Mental State Examination (MMSE)
23-item Alzheimer's Disease Co-operative Study Activities of Daily Living (ADCS-ADL)
12-item Neuropsychiatric Inventory (NPI)
Results
Primary Outcome
ADAS-Cog 11: The study did not meet its primary efficacy endpoint. Both masupirdine doses (50mg and 100mg) showed statistically non-significant differences compared to placebo in change from baseline at week 26[@semba2022].
Secondary Outcomes
No significant treatment effects were observed in:
CDR-SB
MMSE
ADCS-ADL
NPI (overall) in the primary analysis
Safety
Masupirdine was generally safe and well tolerated:
Adverse events similar across treatment arms
No significant differences in serious adverse events
Dose-proportional pharmacokinetics
Agitation Analysis (Post-Hoc)
Exploratory post-hoc analyses on NPI agitation subdomain suggested potential beneficial effects that warrant further investigation in a prospective trial focused on agitation[@menon2022].
Comparison with Other 5-HT6 Antagonists
| Drug | Company | Status | Indication | |------|---------|--------|-------------| | Masupirdine (SUVN-502) | Suven Life Sciences | Phase 2 complete | AD, agitation | | Idalopirdine (Lu AE58054) | Lundbeck/Otsuka | Phase 3 failed | AD | | SB-742457 | GlaxoSmithKline | Phase 2 | AD | | PRX-070980 | Epix Therapeutics | Phase 1/2 | AD |
The 5-HT6 antagonist class has faced challenges in AD clinical trials, with multiple compounds failing to meet primary endpoints.
[Semba J, et al, A phase 2 randomized, double-blind, placebo-controlled study of masupirdine (SUVN-502) as adjunctive therapy in patients with moderate Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35662833/)
Unknown, ClinicalTrials.gov. Study of SUVN-502 in Patients With Moderate Alzheimer's Disease. NCT02580305 (n.d.)
[Menon V, et al, Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses (2022)](https://pubmed.ncbi.nlm.nih.gov/36168659/)
[Geldenhuys WJ, Van der Schyf CJ, Role of serotonin 5-HT6 receptors in neurodegeneration: Therapeutic strategies (2023)](https://pubmed.ncbi.nlm.nih.gov/36830678/)
[Coate L, et al, 5-HT6 receptor antagonists as a novel therapeutic approach for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37450123/)
[Ramirez MJ, et al, Serotonergic drugs and Alzheimer's disease: Future directions (2024)](https://pubmed.ncbi.nlm.nih.gov/37945678/)